Abstract: 【Abstract】 Objective To investigate the efficacy and safety of applying Continuous Albumin Circulating Absorbent System (CACAS) in treatment for critically ill patients with liver failure. Method Thirty critically ill patients with liver failure were treated with CACAS. Patients’ vital signs, liver function, coagulation changes were compared before and after the treatment, and after termination of the treatment for 12h. Results After the treatment, serum bilirubin level (485.46±34.85 μmol/L before treatment, and 305.89±43.54 μmol/L after treatment; P＜0.01), conjugated bilirubin (293.62±25.67 μmol/L before treatment, and 190.85±32.13 μmol/L after treatment; P＜0.01), unconjugated bilirubin (212.98±16.18 μmol/L before treatment, and 159.70±23.57 μmol/L after treatment; P＜0.01) decreased significantly, and prothrombin activity (42±8% before treatment, and 80±3% after treatment; P＜0.01) increased significantly. Consciousness turned to be clear in all patients. Changes of other indicators were insignificant. There were no significant changes of the parameters immediately after treatment and after termination of treatment for 12h. Conclusion CACAS system has ideal efficacy and safety when used in treatment for critically ill patients with liver failure, thus is a choice way of artificial liver as the treatment for liver failure.

Key words: Critically ill, Liver failure, Continuous albumin circulating absorbent system, Efficacy, Safety